Rapport Therapeutics, Inc. Common Stock

RAPP

$47.65

-2.14%

N/A-$1.04

Healthcare

Biotechnology

NASDAQ

Active Trading

Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living ...

Insider Transactions of RAPP

Acquisitions (A)

Since Aug 10, 2026

Disposals (D)

Since Aug 10, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 25, 2026	Ceesay Abraham	director, officer: Chief Executive Officer	Common Stock	D	18,921	$49.57
Aug 25, 2026	Yeleswaram Krishnaswamy	officer: Chief Development Officer	Common Stock	D	20,799	$50.31
Aug 25, 2026	Yeleswaram Krishnaswamy	officer: Chief Development Officer	Common Stock	D	16,201	$51.06
Aug 24, 2026	Yeleswaram Krishnaswamy	officer: Chief Development Officer	Common Stock	D	13,160	$50.00
Aug 19, 2026	Yeleswaram Krishnaswamy	officer: Chief Development Officer	Common Stock	D	404	$49.90

Insider Trading Snapshot

Acquisitions (A)

Disposals (D)

Total Shares Bought

Total Shares Sold

120,984

Monthly Insider Activity

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Transactions by Title - Shares

X-axis: shares, sorted by total shares desc

Transactions by Title - Counts

X-axis: counts, sorted by A+D counts desc

Key People: Buy/Sell Activity and Price

Ceesay Abraham

director, officer: Chief Executive Officer • 6 txns

Yeleswaram Krishnaswamy

officer: Chief Development Officer • 4 txns

Transactions Table

Date	Executive	Title	Security	Side	Shares	Price	Value
Aug 25, 2026	Ceesay Abraham	director, officer: Chief Executive Officer	Common Stock	D	18,921	$49.57	$937,957.49
Aug 25, 2026	Yeleswaram Krishnaswamy	officer: Chief Development Officer	Common Stock	D	20,799	$50.31	$1,046,420.57
Aug 25, 2026	Yeleswaram Krishnaswamy	officer: Chief Development Officer	Common Stock	D	16,201	$51.06	$827,184.18
Aug 24, 2026	Yeleswaram Krishnaswamy	officer: Chief Development Officer	Common Stock	D	13,160	$50.00	$657,977.63
Aug 19, 2026	Yeleswaram Krishnaswamy	officer: Chief Development Officer	Common Stock	D	404	$49.90	$20,159.60
Aug 11, 2026	Ceesay Abraham	director, officer: Chief Executive Officer	Common Stock	D	3,664	$46.90	$171,837.20
Aug 11, 2026	Ceesay Abraham	director, officer: Chief Executive Officer	Common Stock	D	19,500	$48.04	$936,846.30
Aug 11, 2026	Ceesay Abraham	director, officer: Chief Executive Officer	Common Stock	D	5,794	$48.62	$281,721.08
Aug 10, 2026	Ceesay Abraham	director, officer: Chief Executive Officer	Common Stock	D	14,171	$45.97	$651,491.89
Aug 10, 2026	Ceesay Abraham	director, officer: Chief Executive Officer	Common Stock	D	8,370	$46.75	$391,279.92

Supply Chain of RAPP

RELATIONS

Upstream

Small Molecule CDMO (Undisclosed)Clinical CRO (Undisclosed)Thermo Fisher Scientific Inc.NYSE:TMO IQVIA Holdings Inc.NYSE:IQV ICON plcNASDAQ:ICLR Charles River Laboratories International Inc.NYSE:CRLMerck KGaA (MilliporeSigma)XETRA:MRKDanaher CorporationNYSE:DHRLonza Group AGSWX:LONN

Downstream

Tenacia Biotechnology (Hong Kong) Co., Ltd.Third Rock Ventures (Founding Partner)Johnson & Johnson Innovation - JJDC, Inc.NYSE:JNJFuture Specialty Pharmacy & Wholesaler Channel

Proxies

Xenon Pharmaceuticals Inc.NASDAQ:XENE Praxis Precision Medicines, Inc.NASDAQ:PRAX Neurocrine Biosciences, Inc.NASDAQ:NBIX Sage Therapeutics, Inc.NASDAQ:SAGE

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer